Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (4.956)

1

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60) : a randomised, non-comparative, phase 2 study

enthalten in: The Lancet. Oncology | 2024

von Kim, S. | Ghiringhelli, F. | de la Fouchardière, C. | +25

2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis : A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study

enthalten in: Journal of clinical pharmacology | 2024

von Danto, S. | Tsamandouras, N. | Reddy, P. | +6

3

ENTERPRET : A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Jairath, V. | Yarur, A. | Osterman, M. | +6

4

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Milowsky, M. | O'Donnell, P. | Hoimes, C. | +20

5

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2024

von Choueiri, T. | Tomczak, P. | Park, S. | +131

6

In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control

enthalten in: Annals of internal medicine | 2024

von Stanbrook, M.

7

Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis : A phase 2 randomized trial (CBP-201-WW001)

enthalten in: The Journal of allergy and clinical immunology | 2024

von Silverberg, J. | Strober, B. | Feinstein, B. | +13

8

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma : final analysis of the randomized phase 2 FIGHT trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Wainberg, Z. | Kang, Y. | Lee, K. | +15

9

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy

enthalten in: International journal of cancer | 2024

von Masetti, M. | Al-Batran, S. | Goetze, T. | +14

10

Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer : A window-of-opportunity trial

enthalten in: Med (New York, N.Y.) | 2024

von Pan, H. | Yu, M. | Tang, X. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[496]